Supernus Pharmaceuticals Inc. (SUPN)
SUPN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$42.01
-1.87% on the day
Market cap
$2.4B
Mid cap
Revenue · 2025
$719.0M
+8.6% on 2024
Net income · 2025
-$38.6M
-5.4% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | SUPN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2012 |
| SEC CIK | 0001356576 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $719.0M |
| Net income | -$38.6M |
| Operating income | -$62.3M |
| Net margin | -5.4% |
| Operating margin | -8.7% |
| Revenue growth | +8.6% |
| Cash | $128.4M |
| Total assets | $1.5B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.4× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2014-12-04 |
| Latest annual report | 10-K | 2026-03-02 |
| Latest quarterly / interim | 10-Q | 2026-08-03 |
| Latest current report FORM 8-K | 8-K | 2026-08-03 |
| Latest proxy | DEFA14A | 2026-10-06 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.0% |
| 1 month | -0.9% |
| 3 months | -15.1% |
| Year to date | -17.7% |
| 1 year | -15.4% |
| From 52-week high | -28.2% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NAMS | NewAmsterdam Pharma Company N.V. | $20.19 | -4.99% | $2.4B |
| LQDA | Liquidia Corporation | $26.81 | -3.11% | $2.4B |
| SLS | SELLAS Life Sciences Group Inc. | $12.41 | +4.02% | $2.5B |
| VCRE | Vicore Pharma Holding AB | $8.95 | -3.03% | $2.5B |
| MBX | MBX Biosciences Inc. | $49.00 | -5.80% | $2.4B |
| HCM | HUTCHMED (China) Limited | $13.50 | -1.32% | $2.4B |
| ZLAB | Zai Lab Limited | $23.10 | -6.06% | $2.6B |
| PBH | Prestige Consumer Healthcare Inc. | $48.50 | -1.02% | $2.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier